Business

Peptide Cancer Vaccine Market – Global Outlook and Forecast 2022-2028

Peptide Cancer Vaccine

Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.

This report contains market size and forecasts of Peptide Cancer Vaccine in global, including the following market information:

  • Global Peptide Cancer Vaccine Market Revenue, 2017-2022, 2023-2028, ($ millions)
  • Global Peptide Cancer Vaccine Market Sales, 2017-2022, 2023-2028, (K Doses)
  • Global top five Peptide Cancer Vaccine companies in 2021 (%)

 

The global Peptide Cancer Vaccine market was valued at 562.7 million in 2021 and is projected to reach US$ 1895.9 million by 2028, at a CAGR of 18.9% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

ITK-1 Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Peptide Cancer Vaccine include Boston Biomedical, Ultimovacs, BrightPath Biotherapeutics, TapImmune, Immatics, Sellas, Imugene, VAXON Biotech and Generex Biotechnology, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Peptide Cancer Vaccine manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Peptide Cancer Vaccine Market, by Pipeline, 2017-2022, 2023-2028 ($ Millions) & (K Doses)

Global Peptide Cancer Vaccine Market Segment Percentages, by Pipeline, 2021 (%)

  • ITK-1
  • GRN-1201
  • TPIV200
  • TPIV110
  • UV1
  • Galinpepimut-S
  • TARP 27-35
  • HER-Vaxx
  • Vx-001
  • Others

Global Peptide Cancer Vaccine Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Doses)

Global Peptide Cancer Vaccine Market Segment Percentages, by Application, 2021 (%)

  • Breast Cancer
  • Lung Cancer
  • Melanoma
  • Prostate Cancer
  • Others

Global Peptide Cancer Vaccine Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Doses)

Global Peptide Cancer Vaccine Market Segment Percentages, By Region and Country, 2021 (%)

  • North America
  • US
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Russia
  • Nordic Countries
  • Benelux
  • Rest of Europe
  • Asia
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Rest of Asia
  • South America
  • Brazil
  • Argentina
  • Rest of South America
  • Middle East & Africa
  • Turkey
  • Israel
  • Saudi Arabia
  • UAE
  • Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

  • Key companies Peptide Cancer Vaccine revenues in global market, 2017-2022 (Estimated), ($ millions)
  • Key companies Peptide Cancer Vaccine revenues share in global market, 2021 (%)
  • Key companies Peptide Cancer Vaccine sales in global market, 2017-2022 (Estimated), (K Doses)
  • Key companies Peptide Cancer Vaccine sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

  • Boston Biomedical
  • Ultimovacs
  • BrightPath Biotherapeutics
  • TapImmune
  • Immatics
  • Sellas
  • Imugene
  • VAXON Biotech
  • Generex Biotechnology
  • ISA Pharmaceuticals
  • OncoTherapy Science

Table of content

1 Introduction to Research & Analysis Reports
1.1 Peptide Cancer Vaccine Market Definition
1.2 Market Segments
1.2.1 Market by Pipeline
1.2.2 Market by Application
1.3 Global Peptide Cancer Vaccine Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Peptide Cancer Vaccine Overall Market Size
2.1 Global Peptide Cancer Vaccine Market Size: 2021 VS 2028
2.2 Global Peptide Cancer Vaccine Revenue, Prospects & Forecasts: 2017-2028
2.3 Global Peptide Cancer Vaccine Sales: 2017-2028
3 Company Landscape
3.1 Top Peptide Cancer Vaccine Players in Global Market
3.2 Top Global Peptide Cancer Vaccine Companies Ranked by Revenue
3.3 Global Peptide Cancer Vaccine Revenue by Companies
3.4 Global Peptide Cancer Vaccine Sales by Companies
3.5 Global Peptide Cancer Vaccine Price by Manufacturer (2017-2022)
3.6 Top 3 and Top 5 Peptide Cancer Vaccine Companies in Global Market, by Revenue in 2021
3.7 Global Manufacturers Peptide Cancer Vaccine Product Type
3.8 Tier 1, Tier 2 and Tier 3 Peptide Cancer Vaccine Players in Global Market
3.8.1 List of Global Tier 1 Peptide Cancer Vaccine Companies
3.8.2 List of Global Tier 2 and Tier 3 Peptide Cancer Vaccine Companies
4 Sights by Product
4.1 Ov

CONTACT US:
276 5th Avenue, New York, NY 10001, United States
International: +1(646)-781-7170 / +91 8087042414

Similar Reports:

Global Peptide Cancer Vaccine Market Research Report 2022 Professional Edition

Global Peptide Cancer Vaccine Market Outlook 2022

Global and Regional Peptide Cancer Vaccine Industry Status and Prospects Professional Market Research Report Standard Version 2021-2027

Global and United States Peptide Cancer Vaccine Market Insights, Forecast to 2027

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button